CLICK HERE for Breaking Story on Spanish COVID-19 trial:
https://www.dailymail.co.uk/news/article-8502987/Stem-cell-therapy-boosts-Covid-19-survival-rates-FIVE-fold-critically-ill-patients.html
In my opinion, there is a 95% chance that these Stem Cell's were supplied by Mesoblast's licensee Takeda (Alofisel®)
Principal Investigators are:
* Professor Bernat Soria from the Miguel Hernández University (UMH).
* Professor Damián García Olmo from the Fundación Jiménez Díaz.
Initial news story about this Covid-19 trial in Spain:
https://www.elplural.com/sociedad/hospitales-universidades-espanolas-investigan-farmaco-pacientes-graves-coronavirus_236193102
Professor Damián García Olmo's tweet about Mesoblast's licensee Takeda (Alofisel®):
https://twitter.com/garciaolmod/status/977559554580975617
Mesoblast's partnership with Takeda (Alofisel®):
https://www.mesoblast.com/partnerships/overview
More references of Professor Damián García Olmo's work with Mesoblast's licensee Takeda (Alofisel®)
https://elmedicointeractivo.com/takeda-firma-con-el-ministerio-un-acuerdo-de-riesgo-compartido-para-financiar-alofisel/
https://gacetamedica.com/investigacion/la-primera-terapia-celular-alogenica-ya-esta-disponible-en-espana-hi2280180/
Mesoblast's licensee Takeda (Alofisel®) appears to score a big win in Spanish Covid-19 trial
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $5.286M | 5.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 91218 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 63577 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |